Full Press Release Details
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV SLB101 a Proprietary Muscle Targeted Capsid in the Development of an RNAi Therapy to treat FSHD.
SLDB
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV SLB101 a Proprietary Muscle Targeted Capsid in the Development of an RNAi Therapy to treat FSHD
Key Takeaway: Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV SLB101 a Proprietary Muscle Targeted Capsid in the Development of an RNAi Therapy to treat FSHD